Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.
Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference
May 16th 2025For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with platinum-doublet chemotherapy.
Read More